Tulane Home Tulane Shield logo linking to site home page
Home / Martin Moehlen, MD, MPH
Martin Moehlen, MD, MPH
  • Interim Section Chief
  • Director, GI & Hepatology Research, Program Director, GI Fellowship, Associate Professor of Medicine and Surgery
  • 1415 Tulane Avenue, HC-5, New Orleans, LA 70112
  • Clinic: 504-988-5344 | Scroll for more contact info
  • School of Medicine
Martin Moehlen, MD, MPH

Education

  • MD, Tulane University School of Medicine, New Orleans, LA
  • MPH, Tulane University School of Public Health & Tropical Medicine, New Orleans, LA
  • BA, Skidmore College, Saratoga Springs, NY

Biography

doctor icon
CLINIC
504-988-5344
Fax: 504-988-2252

beaker icon with yellow liquid
RESEARCH
504-988-3047
Fax: 504-988-3048

building icon
ACADEMIC OFFICE
504-988-5763
 

Return to Tulane Doctors

 

Dr. Moehlen joined the faculty of Tulane in July 2013 as a transplant hepatologist.  He completed his Internal Medicine residency and Gastroenterology fellowship at Tulane University.  Additionally, he completed a hepatology fellowship at Jackson Memorial Hospital-Leonard Miller School of Medicine University of Miami.  He is triple board certified in internal medicine, gastroenterology, and transplant hepatology by the American Board of Internal Medicine (ABIM). In September 2021 he was named Interim Chief of the Section.

Dr. Moehlen cares for patients at Tulane Hospital and Clinic in New Orleans, LA, University Medical Center-New Orleans Hepatology Clinic, and Tulane outreach clinic in Covington, LA.  He specializes in the treatment for liver disease including cirrhosis and need for liver transplant.  His clinical interests include viral hepatitis, fatty liver/NASH, autoimmune liver disease, alcohol-associated liver disease, cholestatic liver disease - primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC), and genetic diseases of the liver.  He also provides endoscopic evaluation for those needing EGDs and colonoscopies.

In addition to his clinical activities, Dr. Moehlen is the Director of Gastroenterology and Hepatology Research.  He is a site principal investigator for numerous clinical trials in fatty liver/NASH, PBC, PSC, autoimmune hepatitis, viral hepatitis, and hepatocellular carcinoma (see below).  He has published a number of peer-reviewed abstracts and papers. 

He is an active educator in the Tulane University School of Medicine, mentoring gastroenterology fellows, internal medicine residents, and medical students. He serves as the ACGME Program Director for the gastroenterology fellowship. He is a member of the American Association for the Study of Liver Diseases (AASLD), American Society of Transplantation (AST), International Liver Transplantation Society (ILTS), American Gatroenterological Association (AGA), and American College of Gastroenterology (ACG).

Research

Research Grants, Principal Investigator
Click this link to read about Dr. Moehlen's Research Grants

  1. Protocol: LLS-019. Evaluation of the diagnostic performance of the M30 Apoptosense®, M65 and M65 EpiDeath ELISA Assay Results to Stratify Non-Alcoholic Steatohepatitis (NASH) from simple steatosis in a Cohort of Patients Suspected of Non-alcoholic Fatty Liver Disease (NAFLD). Sponsor: diaPharma Group. Year Awarded: 2020. Status: Enrolling.
  2. Protocol: MK7902-012. A phase 3 multicenter, randomized, double-blinded, active-controlled, clinical study to evaluate the safety and efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non- metastatic hepatocellular carcinoma (LEAP-012). Sponsor: Merck Sharp & Dohme Corporation. Year Awarded: 2020. Status: Enrolling.
  3. Protocol: VK2809-202. A phase 2B, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of VK2809 administered for 52 weeks followed by a 4-week off-drug phase in subjects with non-alcoholic steatohepatitis. Sponsor: Viking Therapeutics, Inc. Year Awarded: 2020. Status: Enrolling.
  4. Protocol: CA2099DX. A phase 3, randomized, double-blind study of adjuvant Nivolumab versus placebo for participants with hepatocellular carcinoma who are at high risk of recurrence after curative hepatic resection or ablation. Sponsor: Bristol- Myers Squibb. Year Awarded: 2019. Status: Closed to Enrollment.
  5. Protocol: MB130-069. A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and Compensated Liver Cirrhosis. Sponsor: Bristol-Myers Squibb.Year Awarded: 2019. Status: Closed to Enrollment.
  6. Protocol: MB130-068. A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis. Sponsor: Bristol-Myers Squibb. Year Awarded: 2019. Status: Closed to Enrollment.
  7. Protocol: M14-222. An Open-Label, Multicenter Study to Evaluate Long-term Outcomes With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection. Sponsor: AbbVie Inc. Year Awarded: 2019. Status: Closed.
  8. Protocol: 56136379HPB2001. A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and in Combination With a Nucleos(t)Ide Analog in Subjects With Chronic Hepatitis B Virus Infection. Sponsor: Janssen Sciences Ireland UC.Year Awarded: 2019. Status: Closed.
  9. Protocol: GS-US-454-4378. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH). Sponsor: Gilead Sciences. Year Awarded: 2019. Status: Closed.
  10. Protocol: 3152-301-002. AURORA: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis). Sponsor: Allergan.Year Awarded: 2019. Status: Closed to Enrollment.
  11. Protocol: 3152-201-002. Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis (NASH). Sponsor: Allergan. Year Awarded: 2019. Status: Closed to Enrollment.
  12. Protocol: GS-US-384-1943. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH). Sponsor: Gilead Sciences. Year Awarded: 2019. Status: Closed.
  13. Protocol: GS-US-384-1944. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis. Sponsor: Gilead Sciences. Year Awarded: 2019. Status: Closed.
  14. Protocol: RFHE4043. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy. Sponsor: Salix Pharmaceuticals. Year Awarded: 2019. Status: Open and Not Yet Enrolling.
  15. Protocol: 16HEP01. Procurement of blood samples from subjects with diagnosed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) for use in the development of a liver fibrosis test. Sponsor: Prometheus. Year Awarded: 2019. Status: Closed.
  16. Protocol: MK-5172-017. A Long-Term Follow-Up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated With MK-5172 in a Prior Cinical Trial. Sponsor: Merck Sharp & Dohme Corporation. Year Awarded: 2019. Status: Closed. .
  17. Protocol: CB8025-31735. A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or an intolerance to ursodeoxycholic acid (UDCA). Sponsor: CymaBay Pharmaceuticals. Year Awarded: 2018. Status: Closed.
  18. Protocol: AVA-CLD-401. An Observational Cohort Study of the Use of Avatrombopaq in Patients with Thrombocytopenia Associated with Chronic Liver Disease Undergoing a Procedure. Sponsor: Dova Pharmaceuticals. Year Awarded: 2018. Status: Closed.
  19. Protocol: JKB-122AIH. A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis Patients who are Refractory or Intolerant to Current Therapies. Sponsor: TaiwanJ Pharmaceuticals. Year Awarded: 2017. Status: Closed.
  20. Protocol: GFT505-315-1. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Nonalcoholic Steatohepatitis (NASH) and Fibrosis (RESOLVE-IT). Sponsor: Genfit. Year Awarded: 2016. Status: Closed to Enrollment.
  21. Protocol: 1423M0634. Phase 3 Randomised, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of S-888711 (Lusutrombopag) for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures (L-PLUS 2). Sponsor: Shionogi. Year Awarded: 2015. Status: Closed.
  22. Protocol: GS-US-174-0149. A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination With Peginterferon α-2a (Pegasys) Versus Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Non-Cirrhotic Subjects With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B (CHB). Sponsor: Gilead Sciences.
    Year Awarded: 2014. Status: Closed.
  23. Protocol: GFT505-212-7. A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 Once Daily on Steatohepatitis in Patients With Non-Alcoholic Steatohepatitis (NASH).
    Sponsor: Genfit. Year Awarded: 2014. Status: Closed.

Hide this content.

Investigator Initiated Projects
Click this link to read about Dr. Moehlen's Investigator Initiated Projects

  1. Protocol 2017-197. Endoplasmic reticulum stress markers in advanced chronic liver disease (or Comparison of ER stress markers in HCV related cirrhosis after viral Cure by Interferon or Direct Acting Antiviral therapies). Principal Investigator. Faculty collaborators: Srikanta Dash, PhD and Ali Riza Koksal, MD. Housestaff collaborators/mentees: Molly Plummer, MD (Tulane GI Fellow) and Carlo Basilio, MD (Tulane IM Resident). Status: Active.
  2. Protocol 2018-979. Endoplasmic Reticulum Stress Markers in Hepatitis C cirrhosis, as well as non-viral etiologies of cirrhosis. Principal Investigator. Faculty collaborators: Srikanta Dash, PhD and Ali Riza Koksal, MD. Housestaff collaborators/mentees: Molly Plummer, MD (Tulane GI Fellow) and Carlo Basilio, MD (Tulane IM Resident). Status: Active.
  3. Protocol 2018-1861-TU. Does the Fibroscan® controlled attenuation parameter (CAP) reliably estimate the amount of hepatic steatosis? – The Tulane Medical Center Experience. Principal Investigator. Housestaff collaborator/mentee: Carmen Lopez, MD (Tulane IM resident). Status: Closed.
  4. Protocol 839884. Efficacy of chronic hepatitis C treatment in the Direct Antiviral Agent (DAA) Era – The Tulane Medical Center Experience. Principal Investigator. Housestaff collaborators/mentees: Noor Ali, MD and Justin Miller, MD (Tulane IM residents). Status: Closed.

Hide this content.

 

Publications

Click this link to view some of Dr. Moehlen's Publications

  1. Aydin Y, Chatterjee A, Chandra PK, Chava S, Chen W, Tandon A, Dash A, Chedid M, Moehlen M, Regenstein F, Balart LA, Cohen A, Lu H, Wu T, Dash S. Interferon-alpha induced hepatitis C virus clearance restores p53 tumor suppressor more than direct acting antivirals. Hepatol Commun 2017, doi: 10.1002/hep4.1025.
  2. Moehlen M, Regenstein F. Inpatient management of patients after liver transplantation. Hosp Med Clin 2015;4(4):457-470.
  3. Hauch AT, Buell JF, McGowan M, Bhatia P, Lewin E, Killackey M, Shores NJ, Balart LA, Moehlen M, Saggi B, Paramesh AS. Cutaneous metastases from primary hepatobiliary tumors as the first sign of tumor recurrence following liver transplantation. Case Rep Transplant 2014;2014:838949.
  4. Moehlen M, De Medina M, Hill M, Jeffers L, Schiff ER, Martin P. Absence of hepatitis B resistance mutants before introduction of oral antiviral therapy. ISRN Hepatology 2013 [Article ID 130384, 5 pages, doi:10.1155/2013/130384].
  5. Khan N, Abbas A, Moehlen M, Balart L. Methotrexate in ulcerative colitis: a nationwide retrospective cohort from the Veterans Affairs healthcare system. Inflamm Bowel Dis 2013;19(7):1379-1383.
  6. Papafragkakis H, Rao MS, Moehlen M, Dhillon S, Martin P. Depression and pegylated interferon-based hepatitis C treatment. Int J Infereron Cytokine Mediator Res 2012;4:25-35.
  7. Papafragkakis H, Moehlen M, Garcia MT, Madrazo B, Island E, Martin P. A case of a ruptured sclerosing liver hemangioma. International Journal of Hepatology Epub 2011 May 31.
  8. Feagans J, Victor D, Moehlen M, et al. Interstitial Pneumonitis in the Transplant Patient: Consider Sirolimus-Associated Pulmonary Toxicity. Journal of the Louisiana Medical Society 2009;161(3):166-172.

Nonpublished Works

  1. Moehlen M. Liver Disease Primer. 2019. 6 pages. A syllabus and primer distributed to medical students rotating on the outpatient hepatology clinic.
  2. Moehlen M, Balart L, Regenstein F. Tulane University Liver Transplant and General Hepatology Manual. 2017. 50 pages. A white coat pocket handbook for medical students and housestaff rotating on the inpatient hepatology service.

Hide this content.

Areas of Expertise

Research

Research Grants, Principal Investigator
Click this link to read about Dr. Moehlen's Research Grants

  1. Protocol: LLS-019. Evaluation of the diagnostic performance of the M30 Apoptosense®, M65 and M65 EpiDeath ELISA Assay Results to Stratify Non-Alcoholic Steatohepatitis (NASH) from simple steatosis in a Cohort of Patients Suspected of Non-alcoholic Fatty Liver Disease (NAFLD). Sponsor: diaPharma Group. Year Awarded: 2020. Status: Enrolling.
  2. Protocol: MK7902-012. A phase 3 multicenter, randomized, double-blinded, active-controlled, clinical study to evaluate the safety and efficacy of Lenvatinib (E7080/MK-7902) with Pembrolizumab (MK-3475) in combination with transarterial chemoembolization (TACE) versus TACE in participants with incurable/non- metastatic hepatocellular carcinoma (LEAP-012). Sponsor: Merck Sharp & Dohme Corporation. Year Awarded: 2020. Status: Enrolling.
  3. Protocol: VK2809-202. A phase 2B, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of VK2809 administered for 52 weeks followed by a 4-week off-drug phase in subjects with non-alcoholic steatohepatitis. Sponsor: Viking Therapeutics, Inc. Year Awarded: 2020. Status: Enrolling.
  4. Protocol: CA2099DX. A phase 3, randomized, double-blind study of adjuvant Nivolumab versus placebo for participants with hepatocellular carcinoma who are at high risk of recurrence after curative hepatic resection or ablation. Sponsor: Bristol- Myers Squibb. Year Awarded: 2019. Status: Closed to Enrollment.
  5. Protocol: MB130-069. A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and Compensated Liver Cirrhosis. Sponsor: Bristol-Myers Squibb.Year Awarded: 2019. Status: Closed to Enrollment.
  6. Protocol: MB130-068. A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of BMS-986036 (PEG-FGF21) in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis. Sponsor: Bristol-Myers Squibb. Year Awarded: 2019. Status: Closed to Enrollment.
  7. Protocol: M14-222. An Open-Label, Multicenter Study to Evaluate Long-term Outcomes With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection. Sponsor: AbbVie Inc. Year Awarded: 2019. Status: Closed.
  8. Protocol: 56136379HPB2001. A Phase 2a, Randomized, Partially-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Pharmacokinetics of Treatment With Multiple Doses of JNJ-56136379 as Monotherapy and in Combination With a Nucleos(t)Ide Analog in Subjects With Chronic Hepatitis B Virus Infection. Sponsor: Janssen Sciences Ireland UC.Year Awarded: 2019. Status: Closed.
  9. Protocol: GS-US-454-4378. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Subjects With Bridging (F3) Fibrosis or Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH). Sponsor: Gilead Sciences. Year Awarded: 2019. Status: Closed.
  10. Protocol: 3152-301-002. AURORA: A Phase 3 Study to Evaluate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis). Sponsor: Allergan.Year Awarded: 2019. Status: Closed to Enrollment.
  11. Protocol: 3152-201-002. Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects With Nonalcoholic Steatohepatitis (NASH). Sponsor: Allergan. Year Awarded: 2019. Status: Closed to Enrollment.
  12. Protocol: GS-US-384-1943. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH). Sponsor: Gilead Sciences. Year Awarded: 2019. Status: Closed.
  13. Protocol: GS-US-384-1944. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis. Sponsor: Gilead Sciences. Year Awarded: 2019. Status: Closed.
  14. Protocol: RFHE4043. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial To Evaluate The Efficacy, Safety, And Pharmacokinetics Of Rifaximin 550 Mg In Subjects With Severe Hepatic Impairment And Overt Hepatic Encephalopathy. Sponsor: Salix Pharmaceuticals. Year Awarded: 2019. Status: Open and Not Yet Enrolling.
  15. Protocol: 16HEP01. Procurement of blood samples from subjects with diagnosed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) for use in the development of a liver fibrosis test. Sponsor: Prometheus. Year Awarded: 2019. Status: Closed.
  16. Protocol: MK-5172-017. A Long-Term Follow-Up Study to Evaluate the Durability of Virologic Response and/or Viral Resistance Patterns of Subjects With Chronic Hepatitis C Who Have Been Previously Treated With MK-5172 in a Prior Cinical Trial. Sponsor: Merck Sharp & Dohme Corporation. Year Awarded: 2019. Status: Closed. .
  17. Protocol: CB8025-31735. A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or an intolerance to ursodeoxycholic acid (UDCA). Sponsor: CymaBay Pharmaceuticals. Year Awarded: 2018. Status: Closed.
  18. Protocol: AVA-CLD-401. An Observational Cohort Study of the Use of Avatrombopaq in Patients with Thrombocytopenia Associated with Chronic Liver Disease Undergoing a Procedure. Sponsor: Dova Pharmaceuticals. Year Awarded: 2018. Status: Closed.
  19. Protocol: JKB-122AIH. A Phase 2, Pilot Study of JKB-122 to Assess Liver Tests (ALT) in Autoimmune Hepatitis Patients who are Refractory or Intolerant to Current Therapies. Sponsor: TaiwanJ Pharmaceuticals. Year Awarded: 2017. Status: Closed.
  20. Protocol: GFT505-315-1. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients With Nonalcoholic Steatohepatitis (NASH) and Fibrosis (RESOLVE-IT). Sponsor: Genfit. Year Awarded: 2016. Status: Closed to Enrollment.
  21. Protocol: 1423M0634. Phase 3 Randomised, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of S-888711 (Lusutrombopag) for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures (L-PLUS 2). Sponsor: Shionogi. Year Awarded: 2015. Status: Closed.
  22. Protocol: GS-US-174-0149. A Phase 4, Randomized, Open-label, Active-Controlled, Superiority Study to Evaluate the Efficacy and Safety of Tenofovir Disoproxil Fumarate (TDF) in Combination With Peginterferon α-2a (Pegasys) Versus Standard of Care Tenofovir Disoproxil Fumarate Monotherapy or Peginterferon α-2a Monotherapy for 48 Weeks in Non-Cirrhotic Subjects With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis B (CHB). Sponsor: Gilead Sciences.
    Year Awarded: 2014. Status: Closed.
  23. Protocol: GFT505-212-7. A Multicentre, Randomized, Double Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GFT505 Once Daily on Steatohepatitis in Patients With Non-Alcoholic Steatohepatitis (NASH).
    Sponsor: Genfit. Year Awarded: 2014. Status: Closed.

Hide this content.

Investigator Initiated Projects
Click this link to read about Dr. Moehlen's Investigator Initiated Projects

  1. Protocol 2017-197. Endoplasmic reticulum stress markers in advanced chronic liver disease (or Comparison of ER stress markers in HCV related cirrhosis after viral Cure by Interferon or Direct Acting Antiviral therapies). Principal Investigator. Faculty collaborators: Srikanta Dash, PhD and Ali Riza Koksal, MD. Housestaff collaborators/mentees: Molly Plummer, MD (Tulane GI Fellow) and Carlo Basilio, MD (Tulane IM Resident). Status: Active.
  2. Protocol 2018-979. Endoplasmic Reticulum Stress Markers in Hepatitis C cirrhosis, as well as non-viral etiologies of cirrhosis. Principal Investigator. Faculty collaborators: Srikanta Dash, PhD and Ali Riza Koksal, MD. Housestaff collaborators/mentees: Molly Plummer, MD (Tulane GI Fellow) and Carlo Basilio, MD (Tulane IM Resident). Status: Active.
  3. Protocol 2018-1861-TU. Does the Fibroscan® controlled attenuation parameter (CAP) reliably estimate the amount of hepatic steatosis? – The Tulane Medical Center Experience. Principal Investigator. Housestaff collaborator/mentee: Carmen Lopez, MD (Tulane IM resident). Status: Closed.
  4. Protocol 839884. Efficacy of chronic hepatitis C treatment in the Direct Antiviral Agent (DAA) Era – The Tulane Medical Center Experience. Principal Investigator. Housestaff collaborators/mentees: Noor Ali, MD and Justin Miller, MD (Tulane IM residents). Status: Closed.

Hide this content.

 

 

Honors & Awards

  • Best Doctors in America 2021-2022, New Orleans Magazine

    Best Doctors in America 2019-2020, New Orleans Magazine

  • C. Thorpe Ray, MD Award Recipient, 2006